TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) have earned a consensus rating of “Moderate Buy” from the six analysts that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $40.67.

A number of analysts recently commented on the stock. HC Wainwright lifted their target price on shares of TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. The Goldman Sachs Group boosted their price objective on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. StockNews.com upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 14th. JPMorgan Chase & Co. boosted their price target on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research note on Monday, November 25th. Finally, TD Cowen initiated coverage on TG Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price objective for the company.

Insider Activity

In other TG Therapeutics news, Director Sagar Lonial sold 5,000 shares of the stock in a transaction on Monday, November 11th. The shares were sold at an average price of $30.44, for a total transaction of $152,200.00. Following the transaction, the director now directly owns 100,195 shares of the company’s stock, valued at $3,049,935.80. This trade represents a 4.75 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 10.50% of the company’s stock.

Institutional Investors Weigh In On TG Therapeutics

Several large investors have recently bought and sold shares of the company. NBC Securities Inc. boosted its position in shares of TG Therapeutics by 58.9% during the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 485 shares during the last quarter. Ashton Thomas Private Wealth LLC acquired a new stake in shares of TG Therapeutics during the 2nd quarter worth about $35,000. Blue Trust Inc. raised its holdings in TG Therapeutics by 127.3% in the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 849 shares during the period. ORG Wealth Partners LLC acquired a new position in TG Therapeutics in the third quarter valued at about $53,000. Finally, Values First Advisors Inc. purchased a new position in TG Therapeutics during the third quarter worth about $58,000. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

TG Therapeutics Price Performance

NASDAQ TGTX opened at $30.95 on Friday. The firm’s fifty day simple moving average is $29.42 and its two-hundred day simple moving average is $23.79. The firm has a market capitalization of $4.82 billion, a P/E ratio of -309.47 and a beta of 2.25. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. TG Therapeutics has a 12-month low of $12.84 and a 12-month high of $36.84.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.01). The business had revenue of $83.90 million for the quarter, compared to analysts’ expectations of $81.68 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The firm’s quarterly revenue was down 49.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.73 earnings per share. Analysts forecast that TG Therapeutics will post 0.17 EPS for the current fiscal year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.